ITCI - Intra-Cellular Therapies Inc Stock Price, Fair Value and News

66.98USD-4.23 (-5.94%)Market Closed

Market Summary

USD66.98-4.23

Market Closed

-5.94%

ITCI Alerts

Big jump in Revenue (Y/Y)

Big jump in Earnings (Y/Y)
Losses in recent quarter

ITCI Stock Price

View Fullscreen

ITCI RSI Chart

ITCI Valuation

Market Cap

7.5B

Price/Earnings (Trailing)

-67.81

Price/Sales (Trailing)

14.63

EV/EBITDA

-67.45

Price/Free Cashflow

-76.31

ITCI Price/Sales (Trailing)

ITCI Profitability

EBT Margin

-21.38%

Return on Equity

-18.49%

Return on Assets

-14.84%

Free Cashflow Yield

-1.31%

ITCI Fundamentals

ITCI Revenue

Revenue (TTM)

513.9M

Rev. Growth (Yr)

52%

Rev. Growth (Qtr)

9.66%

ITCI Earnings

Earnings (TTM)

-110.9M

Earnings Growth (Yr)

65.39%

Earnings Growth (Qtr)

46.65%

Breaking Down ITCI Revenue

52 Week Range

50.7471.22

(Low)(High)

Last 7 days

-1.0%

Last 30 days

3.9%

Last 90 days

3.7%

Trailing 12 Months

11.0%

How does ITCI drawdown profile look like?

ITCI Financial Health

Current Ratio

5.12

ITCI Investor Care

Shares Dilution (1Y)

10.06%

Diluted EPS (TTM)

-1.16

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	513.9M	0	0	0
2023	310.6M	365.8M	420.1M	464.4M
2022	102.9M	138.5M	188.1M	250.3M
2021	37.6M	55.7M	70.6M	83.8M
2020	9.3M	13.8M	18.3M	22.8M
2019	0	0	0	4.8M
2017	426.0K	312.3K	338.7K	245.8K
2016	0	316.5K	263.5K	361.4K
2015	0	466.9K	247.7K	153.9K
2014	2.3M	1.9M	1.3M	577.3K
2013	3.1M	2.3M	2.6M	2.7M
2012	0	16.6M	9.9M	3.1M
2011	0	0	0	23.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Intra-Cellular Therapies Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 24, 2024	mates sharon	acquired	345,618	17.2637	20,020	chairman and ceo
Mar 31, 2024	van nostrand robert l	acquired	5,466	69.2	79.00	-
Mar 31, 2024	riggs rory b	acquired	17,992	69.2	260	-
Mar 20, 2024	riggs rory b	acquired	371,200	18.56	20,000	-
Mar 11, 2024	mates sharon	sold	-1,341,120	65.2139	-20,565	chairman, president & ceo
Mar 11, 2024	hineline lawrence j.	sold	-667,587	65.9606	-10,121	svp of finance, cfo
Mar 11, 2024	neumann mark	sold	-481,931	65.6135	-7,345	evp, chief commercial officer
Mar 11, 2024	halstead michael	sold	-484,537	65.9683	-7,345	evp and general counsel
Mar 11, 2024	durgam suresh k.	sold	-243,482	65.5933	-3,712	evp, chief medical officer
Mar 10, 2024	halstead michael	acquired	-	-	7,345	evp and general counsel

Which funds bought or sold ITCI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 06, 2024	TEACHER RETIREMENT SYSTEM OF TEXAS	reduced	-3.65	-99,000	1,334,000	0.01%
May 06, 2024	Envestnet Portfolio Solutions, Inc.	reduced	-5.14	-28,480	312,646	-%
May 06, 2024	SG Americas Securities, LLC	added	50.84	100,000	318,000	-%
May 06, 2024	Van Hulzen Asset Management, LLC	reduced	-7.02	-41,000	367,000	0.02%
May 06, 2024	Advisory Services Network, LLC	sold off	-100	-31,656	-	-%
May 06, 2024	Jefferies Financial Group Inc.	added	18,025	2,068,650	2,076,980	0.01%
May 06, 2024	First Turn Management, LLC	reduced	-4.93	-1,267,860	14,304,100	2.14%
May 06, 2024	NEW YORK LIFE INVESTMENT MANAGEMENT LLC	reduced	-7.24	-79,210	683,973	0.01%
May 06, 2024	Parallel Advisors, LLC	added	2.24	-1,363	110,651	-%
May 06, 2024	HighTower Advisors, LLC	reduced	-0.77	-12,000	238,000	-%

Are Funds Buying or Selling ITCI?

Are funds buying ITCI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ITCI

No. of Funds

Unveiling Intra-Cellular Therapies Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	9.45%	9,094,302	SC 13G/A
Feb 09, 2024	wasatch advisors lp	-	0	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 08, 2024	wellington management group llp	1.83%	1,763,475	SC 13G/A
Jan 25, 2024	blackrock inc.	8.5%	8,192,987	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	8.78%	8,319,249	SC 13G/A
Feb 06, 2023	wellington management group llp	5.71%	5,409,685	SC 13G
Feb 03, 2023	blackrock inc.	7.9%	7,449,529	SC 13G/A
Jan 10, 2023	wasatch advisors inc	-	0	SC 13G/A

Recent SEC filings of Intra-Cellular Therapies Inc

View All Filings

Date Filed	Form Type	Document
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Apr 25, 2024	4	Insider Trading
Apr 24, 2024	8-K	Current Report
Apr 18, 2024	424B5	Prospectus Filed
Apr 18, 2024	8-K	Current Report
Apr 16, 2024	8-K	Current Report

Peers (Alternatives to Intra-Cellular Therapies Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	357.8B	85.6B	-2.43%	-8.39%	9.3	4.18	5.68%	202.39%
MRK	330.2B	61.4B	1.86%	10.13%	143.19	5.38	6.11%	-82.30%
AMGN	161.1B	29.5B	11.28%	28.04%	42.82	5.46	12.76%	-52.47%
PFE	156.8B	46.5B	4.16%	-28.19%	-112.94	3.37	42.59%	-114.62%
GILD	81.5B	27.1B	-5.96%	-16.75%	14.39	3.01	-0.60%	23.36%
TEVA	15.6B	15.8B	-2.04%	54.08%	-27.14	0.99	6.17%	76.47%
MID-CAP
ALKS	4.2B	1.7B	-5.86%	-20.45%	9.58	2.41	54.01%	364.56%
PRGO	4.1B	4.6B	-3.95%	-16.22%	-533.77	0.9	-0.06%	94.55%
BHC	2.7B	9.0B	-28.82%	23.71%	-5.97	0.3	10.01%	-27.45%
AMPH	2.1B	644.4M	2.42%	17.52%	14.96	3.19	29.14%	50.51%
SMALL-CAP
TLRY	1.5B	743.2M	-23.46%	-28.42%	-4.38	2.07	24.65%	80.36%
TXMD	23.2M	1.3M	-9.05%	-48.20%	-2.26	17.8	-98.14%	-109.18%
ACRX	17.0M	-	-15.25%	35.14%	-0.92	0.22	2882.68%	-138.52%
AGRX	2.7M	19.6M	31.03%	-94.02%	-0.19	0.14	80.00%	43.08%
ACOR	1.1M	117.6M	-57.29%	-90.96%	0	0.01	-0.79%	-283.60%

Intra-Cellular Therapies Inc News

Latest updates

Intra-Cellular Therapies Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2017Q4	2017Q3	2017Q2
Revenue	9.7%	144,866,000	132,099,000	126,173,000	110,792,000	95,306,000	87,869,000	71,870,000	55,579,000	34,996,000	25,671,000	22,207,000	20,047,000	15,878,000	12,454,291	7,368,594	1,906,636	1,083,479	544,267	5,055	30,754	114,741
Operating Expenses	-0.2%	165,818,000	166,196,000	155,886,000	157,971,000	143,698,000	135,281,000	127,499,000	143,502,000	107,658,000	111,675,000	99,531,000	89,188,000	69,097,000	73,787,606	63,305,048	66,778,953	50,169,003	41,829,272	-	-	-
S&GA Expenses	-100.0%	-	104,720,000	105,207,000	101,014,000	98,923,000	94,631,000	88,375,000	100,316,000	75,460,000	79,678,000	70,498,000	69,851,000	52,584,000	58,348,504	52,473,573	41,445,557	34,096,366	22,763,547	-	-	-
R&D Expenses	-15.6%	42,833,000	50,774,000	41,550,000	49,794,000	38,024,000	33,862,000	33,274,000	38,536,000	29,043,000	29,458,000	27,032,000	17,297,000	15,058,000	14,298,449	10,275,368	25,204,857	16,003,326	19,065,726	-	-	-
EBITDA Margin	28.7%	-0.21	-0.30	-0.37	-0.50	-0.73	-1.02	-1.58	-2.32	-2.94	-3.38	-3.66	-4.25	-	-	-	-	-	-	-	-	-
Income Taxes	-19.9%	359,000	448,000	43,000	135,000	10,000	-	1,000	-	5,000	6,000	23,000	-24,000	-5,000	-10,232	-	-	-3,281	-	-	-	-
Earnings Before Taxes	47.1%	-14,888,000	-28,131,000	-24,215,000	-42,649,000	-44,043,000	-44,026,000	-53,507,000	-86,603,000	-72,114,000	-85,734,000	-76,931,000	-68,720,000	-52,735,000	-60,688,796	-55,183,625	-63,712,258	-47,407,321	-40,582,851	-	-	-
EBT Margin	28.6%	-0.21	-0.30	-0.37	-0.50	-0.73	-1.02	-1.58	-2.32	-2.95	-3.39	-3.67	-4.26	-	-	-	-	-	-	-	-	-
Net Income	46.6%	-15,247,000	-28,579,000	-24,258,000	-42,784,000	-44,053,000	-44,026,000	-53,508,000	-86,603,000	-72,119,000	-85,734,000	-76,908,000	-68,744,000	-52,740,000	-60,699,178	-55,183,625	-63,712,258	-47,410,602	-40,582,851	-	-	-
Net Income Margin	28.3%	-0.22	-0.30	-0.37	-0.50	-0.73	-1.02	-1.58	-2.32	-2.95	-3.39	-3.67	-4.26	-	-	-	-	-	-	-	-	-
Free Cashflow	-1554.6%	-34,117,000	-2,062,000	-25,538,000	-36,802,000	-60,066,000	-39,165,000	-53,468,000	-94,916,000	-83,415,000	-73,185,000	-79,576,000	-59,341,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	2.6%	747	728	718	714	722	755	782	812	869	490	557	626	674	717	771	441	481	251	281	310	343
Current Assets	3.4%	691	668	702	698	706	738	760	789	848	467	533	601	649	691	745	419	461	230	259	288	321
Cash Equivalents	-4.2%	142	148	99.00	142	76.00	149	135	77.00	129	92.00	106	121	130	61.00	301	129	180	108	102	92.00	64.00
Inventory	36.9%	16.00	12.00	43.00	42.00	28.00	24.00	24.00	25.00	8.00	8.00	8.00	8.00	8.00	7.00	3.00	2.00	1.00	-	-	-	-
Net PPE	-8.0%	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00
Liabilities	7.8%	148	137	117	107	95.00	99.00	97.00	90.00	76.00	72.00	70.00	72.00	62.00	60.00	62.00	61.00	51.00	56.00	54.00	53.00	54.00
Current Liabilities	9.1%	135	124	103	92.00	80.00	83.00	77.00	71.00	59.00	53.00	50.00	50.00	40.00	37.00	38.00	40.00	31.00	36.00	33.00	33.00	33.00
Shareholder's Equity	1.4%	599	591	601	607	628	656	685	722	793	418	487	554	612	657	709	380	430	195	227	257	289
Retained Earnings	-0.9%	-1,632	-1,617	-1,588	-1,564	-1,521	-1,477	-1,433	-1,379	-1,293	-1,221	-1,135	-1,058	-989	-937	-876	-821	-757	-710	-669	-634	-597
Additional Paid-In Capital	1.1%	2,232	2,208	2,191	2,174	2,152	2,138	2,124	2,107	2,089	1,639	1,622	1,612	1,602	1,593	1,585	1,200	1,188	905	896	891	886
Shares Outstanding	1.1%	97.00	96.00	96.00	96.00	96.00	95.00	94.00	94.00	93.00	81.00	81.00	81.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	6,000	-	-	-	-	-	-	-	5,300	-	-	-	3,200	-	-	-	614	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-1555.3%	-34,116	-2,061	-25,270	-36,802	-60,066	-39,193	-53,351	-94,793	-82,849	-73,184	-79,267	-59,326	-47,767	-68,242	-63,579	-47,024	-51,226	-35,055	-29,989	-27,308	-35,629
Share Based Compensation	-6.8%	13,843	14,856	14,311	13,226	10,439	11,159	11,751	11,998	8,105	9,378	9,530	8,617	6,778	4,763	6,901	6,947	5,504	5,939	4,807	4,987	5,055
Cashflow From Investing	-65.9%	16,179	47,422	-20,167	94,748	-16,462	50,263	106,170	37,229	-322,035	51,509	63,772	48,794	116,269	-176,335	-143,216	-7,757	-152,984	37,737	40,237	54,722	44,742
Cashflow From Financing	232.5%	9,989	3,004	2,581	8,585	3,640	2,187	5,654	5,504	441,814	7,914	591	1,582	1,432	3,635	378,494	4,480	277,567	2,793	152	259	31.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ITCI Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Total revenues, net	$ 464,370	$ 250,314	$ 83,803
Operating expenses:
Cost of product sales	33,745	20,443	8,035
Selling, general and administrative	409,864	358,782	272,611
Research and development	180,142	134,715	88,845
Total operating expenses	623,751	513,940	369,491
Loss from operations	(159,381)	(263,626)	(285,688)
Interest income	20,343	7,376	1,568
Loss before provision for income taxes	(139,038)	(256,250)	(284,120)
Income tax expense	(636)	(6)	(6)
Net loss	$ (139,674)	$ (256,256)	$ (284,126)
Net loss per common share:
Basic (in dollars per share)	$ (1.46)	$ (2.72)	$ (3.50)
Diluted (in dollars per share)	$ (1.46)	$ (2.72)	$ (3.50)
Weighted average number of common shares:
Basic (in shares)	95,881,729	94,046,670	81,253,394
Diluted (in shares)	95,881,729	94,046,670	81,253,394
Product sales, net
Total revenues, net	$ 462,175	$ 249,132	$ 81,708
Grant revenue
Total revenues, net	$ 2,195	$ 1,182	$ 2,095

ITCI Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 147,767	$ 148,615
Investment securities, available-for-sale	350,174	443,290
Restricted cash	1,750	1,750
Accounts receivable, net	114,018	75,189
Inventory	11,647	23,920
Prepaid expenses and other current assets	42,443	45,193
Total current assets	667,799	737,957
Property and equipment, net	1,654	1,913
Right of use assets, net	12,928	14,824
Inventory, non-current	38,621	0
Other assets	7,293	86
Total assets	728,295	754,780
Current liabilities:
Accounts payable	11,452	10,395
Accrued and other current liabilities	27,944	19,657
Accrued customer programs	53,173	25,621
Accrued employee benefits	27,364	22,996
Operating lease liabilities	3,612	4,567
Total current liabilities	123,545	83,236
Operating lease liabilities, non-current	13,326	15,474
Total liabilities	136,871	98,710
Stockholders’ equity:
Common stock, $0.0001 par value: 175,000,000 shares authorized at December 31, 2023 and December 31, 2022, respectively; 96,379,811 and 94,829,794 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	10	9
Additional paid-in capital	2,208,470	2,137,737
Accumulated deficit	(1,617,160)	(1,477,486)
Accumulated comprehensive income (loss)	104	(4,190)
Total stockholders’ equity	591,424	656,070
Total liabilities and stockholders’ equity	$ 728,295	$ 754,780

About Intra-Cellular Therapies Inc

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, heart failure, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

CEO	Dr. Sharon Mates Ph.D.
WEBSITE	intracellulartherapies.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	561

Intra-Cellular Therapies Inc Frequently Asked Questions

What is the ticker symbol for Intra-Cellular Therapies Inc? What does ITCI stand for in stocks?

ITCI is the stock ticker symbol of Intra-Cellular Therapies Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Intra-Cellular Therapies Inc (ITCI)?

As of Tue May 07 2024, market cap of Intra-Cellular Therapies Inc is 7.52 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ITCI stock?

You can check ITCI's fair value in chart for subscribers.

What is the fair value of ITCI stock?

You can check ITCI's fair value in chart for subscribers. The fair value of Intra-Cellular Therapies Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Intra-Cellular Therapies Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ITCI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Intra-Cellular Therapies Inc a good stock to buy?

The fair value guage provides a quick view whether ITCI is over valued or under valued. Whether Intra-Cellular Therapies Inc is cheap or expensive depends on the assumptions which impact Intra-Cellular Therapies Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ITCI.

What is Intra-Cellular Therapies Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, ITCI's PE ratio (Price to Earnings) is -67.81 and Price to Sales (PS) ratio is 14.63. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ITCI PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Intra-Cellular Therapies Inc's stock?

In the past 10 years, Intra-Cellular Therapies Inc has provided 0.161 (multiply by 100 for percentage) rate of return.